Ashutosh Tewari, MD
Urology · New York, NYNPI 1790873065
Payments from drug & device makers
Across 257 payments — averaging $9731.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$886K
- Blue Earth Diagnostics$656K
- Bayer$308K
- Merck$250K
- Dendreon Pharmaceuticals LLC$243K
- Gilead$85K
- plus $72K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 23 | $886,381 |
| Blue Earth Diagnostics | 19 | $656,388 |
| Bayer | 122 | $307,587 |
| Merck | 1 | $249,943 |
| Dendreon Pharmaceuticals LLC | 23 | $243,440 |
| Gilead | 21 | $85,082 |
| Sumitomo Pharma America, Inc. | 11 | $36,376 |
| Macrogenics, Inc. | 1 | $32,460 |
| Medtronic | 2 | $1,243 |
| Johnson & Johnson | 5 | $1,212 |
| Pfizer | 3 | $181 |
| Myriad Genetic Laboratories, Inc. | 7 | $125 |
| AbbVie | 4 | $87 |
| Intuitive Surgical | 1 | $53 |
| Caris MPI, Inc. | 1 | $47 |
| Profound Medical Corp. | 1 | $46 |
| Verity Pharmaceuticals Inc. | 2 | $46 |
| Axogen | 1 | $40 |
| Urogen Pharma, Inc. | 1 | $32 |
| Ambu Inc. | 1 | $30 |
| Telix Pharmaceuticals | 1 | $28 |
| Coloplast | 1 | $27 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
| Procept Biorobotics Corporation | 1 | $19 |
| Astellas Pharma US Inc | 1 | $16 |
| Hollister Incorporated | 1 | $14 |
| EDAP Technomed Inc | 1 | $6 |
How this compares
$2,500,931 in reported general payments places this provider in the 95th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other urology in New York
- Guarionex DecastroNew York$5.7M
- James McKiernanNew York$4.1M
- William HuangNew York$3.9M
- Bilal ChughtaiNew York$1.5M
- Nils Peter WiklundNew York$1M
- Herbert LeporNew York$823K
- Christopher AndersonNew York$785K
- Katie MurrayNew York$776K
- John SfakianosNew York$726K
- Alexander SankinNew York$701K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.